濟川藥業(600566.SH):擬3000萬元認購基金份額
格隆匯5月12日丨濟川藥業(600566.SH)公佈,公司為了更好地抓住醫藥行業的發展機遇,提升資產運作水平,提高資金收益,由公司全資子公司濟川有限於2023年5月11日簽訂了《蘇州杏澤興湧新興醫療產業投資基金管理合夥企業(有限合夥)之合夥協議》(稱“合夥協議”),作為有限合夥人以自有資金參與認購蘇州杏澤興湧的出資份額人民幣3000萬元,佔基金本次總認繳出資額的6%。
蘇州杏澤興湧對未上市企業進行股權和/或符合法律規定及合夥協議約定的其它投資,從而使合夥人獲取良好回報,主要投資於如下領域:創新生物醫藥,生物治療和生物工程產品,包括且不僅限於大分子生物藥、小分子靶向藥物、細胞治療、基因治療等;創新醫療器械,包括且不僅限於創新類耗材和器械;以及研發合同外包(CRO)、循環腫瘤檢測等產業鏈相關領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.